Skip to Content

EchoGen

Active Substance: dodecafluoropentane
Common Name: dodecafluoropentane
ATC Code: V08DA
Marketing Authorisation Holder: Sonus Pharmaceuticals Ltd.
Active Substance: dodecafluoropentane
Status: Withdrawn
Authorisation Date: 1998-07-17
Therapeutic Area: Echocardiography
Pharmacotherapeutic Group: Contrast media

Therapeutic Indication

EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.

EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.

The marketing authorisation for EchoGen has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide